Bibliography
- Holtzman SG. Suppression of appetitive behaviour in the rat by naloxone: lack of prior morphine dependence. Life Sci 1979;24:219-26
- Bodnar RJ. Opioid receptor subtype antagonists and ingestion. In: Cooper SJ, Clifton PG, editors, Drug receptor subtypes and ingestive behaviour. London: Academic Press; 1996. p. 127-46
- Gosnell B, Levine AS. Stimulation of ingestive behaviour by preferential and selective opioid agonists. In: Cooper SJ, Clifton PG, editors, Drug receptor subtypes and ingestive behaviour. San Diego: Academic Press; 1996. p. 147-66
- Tepperman TS, Hirst M, Gowdey CW. Hypothalamic injection of morphine: feeding and temperature responses. Life Sci 1981;28:2459-67
- Evans KR, Vaccarino AL. Amphetamine-induced and morphine-induced feeding – evidence for involvement in reward processes. Neurosci Biobehav Rev 1990;14:9-22
- Dum J, Gramsch C, Herz A. Activation of hypothalamic beta-endorphin pools by reward induced by highly palatable food. Pharmacol Biochem Behav 1983;18:443-7
- Yamamoto T, Sako N, Maeda S. Effects of taste stimulation on beta-endorphin levels in rat cerebrospinal fluid and plasma. Physiol Behav 2000;69:345-50
- Cooper SJ, Kirkham TC. Basic mechanisms of opioids' effects on eating and drinking. In: Reid LD, editor. Opioids, bulimia and alcohol abuse and alcoholism. New York: Springer; 1990. p. 91-110
- Yeomans MR, Gray RW. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev 2002;26:713-28
- Morley JE, Parker S, Levine AS. Effect of butorphanol tartrate on food and water consumption in humans. Am J Clin Nutr 1985;42:1175-8
- Drewnowski A, Krahn DD, Demitrack MA, et al. Taste responses and preferences for sweet high-fat foods: evidence for opioid involvement. Physiol Behav 1992;51:371-9
- Facchinetti F, Giovannini C, Barletta C, et al. Hyperendorphinemia in obesity and relationships to affective state. Physiol Behav 1986;36:937-40
- Scavo D, Barletta C, Vagini D, et al. Hyperendorphinemia in obesity is not related to the affective state. Physiol Behav 1990;48:681-3
- Shader RI. Antagonists, inverse agonists, and protagonists. J Clin Psychopharmacol 2003;23:321-2
- Vivitrol prescribing information, October 2007. Alkermes, Inc./Cephalon, Inc
- Sternbach HA, Annitto W, Pottash ALC, et al. Anorexic effects of naltrexone in man. Lancet 1982;1:388-9
- Bertino M, Beauchamp GK, Engelman K. Naltrexone, an opioid blocker, alters taste perception and nutrient intake in humans. Am J Physiol 1991;261:R59-63
- Yeomans MR, Gray RW. Selective effects of naltrexone on food pleasantness and intake. Physiol Behav 1996;60:439-46
- Yeomans MR, Gray RW. Effects of naltrexone on food intake and changes in subjective appetite during eating: evidence for opioid involvement in the appetiser effect. Physiol Behav 1997;62:15-21
- Spiegel TA, Stunkard AJ, Shrager EE, et al. Effect of naltrexone on food intake, hunger, and satiety in obese men. Physiol Behav 1987;40:135-41
- Atkinson RL, Berke LK, Drake CR, et al. Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther 1985;38:419-22
- Maggio CA, Presta E, Bracco EF, et al. Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men. Brain Res Bull 1985;14:657-61
- Malcolm R, O'Neil PM, Sexauer JD, et al. A controlled trial of naltrexone in obese humans. Int J Obes 1985;9:347-53
- Korner J, Leibel RL. To eat or not to eat – how the gut talks to the brain. N Engl J Med 2003;349:926-8
- Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci 2005;8:571-8
- Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002;10:633-41
- Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity 2008;17:30-9
- Fujioka K, Lee MW. Pharmacologic treatment options for obesity: current and potential medications. Nutr Clin Pract 2007;22:50-4
- U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: developing products for weight management. February 2007. Available from: http://www.fda.gov/cder/guidance/7544dft.htm.
- Available from: http://www.orexigen.com/trials. [Accessed 17 May 2009]